Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | VCP | P55072 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | ABL2 | P42684 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | FBP1 | P09467 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1245813 | 1.00 | NPC1 (0.57) | NPC1MTORRAB9AVCPABL1 | |
| SCHEMBL1245814 | 1.00 | NPC1 (0.57) | NPC1MTORRAB9AVCPABL1 | |
| SCHEMBL13904682 | 0.81 | NPC1 (0.56) | NPC1MTORRAB9AVCPALDH1A1 | |
| SCHEMBL13904548 | 0.79 | NPC1 (0.55) | NPC1MTORRAB9AVCPALDH1A1 | |
| SCHEMBL1613583 | 0.79 | NPC1 (0.55) | NPC1MTORRAB9AVCPALDH1A1 | |
| SCHEMBL6023661 | 0.79 | NPC1 (0.51) | NPC1MTORRAB9AVCPALDH1A1 | |
| SCHEMBL6023664 | 0.79 | NPC1 (0.51) | NPC1MTORRAB9AVCPALDH1A1 | |
| SCHEMBL11078650 | 0.79 | CRHBP (0.52) | NPC1MTORRAB9AVCPALDH1A1 | |
| SCHEMBL9146862 | 0.79 | CYP3A4 (0.59) | ALDH1A1HSD17B10TDP1CYP3A4CYP1A2 | |
| SCHEMBL10063347 | 0.78 | NPC1 (0.54) | NPC1MTORRAB9AVCPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200237717-A1 | Treatment of Staphylococcal and Enterococcal Infections Using Substituted Nitrostyrene Compounds | Opal Biosciences Limited (AU) | 2020-07-30 | — | — | US | claimed |
| EP-2854799-B1 | 3,4-METHYLENEDIOXY-BETA-METHYL-BETA-NITROSTYRENE FOR USE IN THE TREATMENT OF SCEDOSPORIUM SPP. INFECTION | OPAL BIOSCIENCES LTD (AU) | 2018-04-25 | — | — | EP | claimed |
| US-9867802-B2 | Method of treating Scedosporium spp. infection | BIODIEM LIMITED (AU) | 2018-01-16 | — | — | US | claimed |
| EP-2468276-B1 | Nitrostyrene derivatives having antimicrobial action | BIODIEM LTD (AU) | 2015-11-11 | — | — | EP | claimed |
| EP-2471531-B1 | Nitro-styrene derivatives having antimicrobial activity | BIODIEM LTD (AU) | 2015-11-04 | — | — | EP | claimed |
| EP-2468275-B1 | Nitrostyrene derivatives with antimicrobial action | BIODIEM LTD (AU) | 2015-11-04 | — | — | EP | claimed |
| US-20150258059-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | BIODIEM LTD (AU) | 2015-09-17 | — | — | US | claimed |
| US-9045452-B2 | Antimicrobial and radioprotective compounds | BIODIEM LTD. (AU) | 2015-06-02 | — | — | US | claimed |
| US-20140080876-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | BIODIEM LTD (AU) | 2014-03-20 | — | — | US | claimed |
| US-8569363-B2 | Antimicrobial and radioprotective compounds | BIODIEM LTD. (AU) | 2013-10-29 | — | — | US | claimed |
| EP-1404665-B1 | ANTIMICROBIAL COMPOUNDS | BIODIEM LTD (AU) | 2012-08-08 | — | — | EP | claimed |
| EP-2471531-A2 | Nitro-styrene derivatives having antimicrobial activity | Biodiem Ltd. (AU) | 2012-07-04 | — | — | EP | claimed |
| EP-2468276-A1 | Nitrostyrene derivatives having antimicrobial action | Biodiem Ltd. (AU) | 2012-06-27 | — | — | EP | claimed |
| EP-2468275-A1 | Nitrostyrenederivatives with antimicrobial action | Biodiem Ltd. (AU) | 2012-06-27 | — | — | EP | claimed |
| US-8158664-B2 | Antimicrobial and radioprotective compounds | BIODIEM LTD. (AU) | 2012-04-17 | — | — | US | claimed |
| US-20100292317-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | BIODIEM LTD. (AU) | 2010-11-18 | — | — | US | claimed |
| US-7825145-B2 | Antimicrobial and radioprotective compounds | BIODIEM LTD (AU) | 2010-11-02 | — | — | US | claimed |
| US-20090012137-A1 | administering microbiocides such as 3,4-methylenedioxy- beta -nitrostyrene, for the treatment of urogenital disorders caused by Candida, Neisseria, Chlamydia or Trichomonas; side effect reduction of radiotherapy | BIODIEM LTD. (AU) | 2009-01-08 | — | — | US | claimed |
| US-20060100258-A1 | Growth promotion method | BIODIEM LTD. (AU) | 2006-05-11 | — | — | US | claimed |
| US-20040266844-A1 | Antimicrobial and radioprotective compounds | BIODIEM LTD (AU) | 2004-12-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200237717-A1 | Treatment of Staphylococcal and Enterococcal Infections Using Substituted Nitrostyrene Compounds | APP, AHR, ESD | NPC1 268/4885MTOR 1703/4885RAB9A 2868/4885 |
| US-20040266844-A1 | Antimicrobial and radioprotective compounds | VIP, XPA, ERCC4 | NPC1 527/4885MTOR 1674/4885RAB9A 958/4885 |
| US-20140080876-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | RAD51, BRCA1, XPA | NPC1 1591/4885MTOR 2604/4885RAB9A 451/4885 |
| US-20150258059-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | RAD51, BRCA1, XPA | NPC1 1591/4885MTOR 2604/4885RAB9A 451/4885 |
| US-20100292317-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | RAD51, BRCA1, XPA | NPC1 1591/4885MTOR 2604/4885RAB9A 451/4885 |
| US-20090012137-A1 | administering microbiocides such as 3,4-methylenedioxy- beta -nitrostyrene, for the treatment of urogenital disorders caused by Candida, Neisseria, Chlamydia or Trichomonas; side effect reduction of radiotherapy | TUBB1, UGT1A1, CYP1A1 | NPC1 695/4885MTOR 3796/4885RAB9A 1109/4885 |
| US-20060100258-A1 | Growth promotion method | HDGF, MKI67, GHRHR | NPC1 3101/4885MTOR 617/4885RAB9A 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.